The Biden administration has announced plans to broaden access to anti-obesity medications, like Ozempic and Wegovy, for individuals enrolled in Medicare and Medicaid. This new proposal from the Department of Health and Human Services (HHS) aims to help those suffering from obesity, a condition that affects millions in the United States.
Currently, Medicare only pays for these medications if the patient has diabetes or cardiovascular disease along with obesity. Although some Medicaid programs in various states do cover these treatments for obesity, many do not, leaving many individuals without assistance.
The HHS proposal would require both Medicare and Medicaid to provide coverage for these anti-obesity drugs as a viable treatment for obesity itself. A White House spokesperson noted that this change could help about 3.4 million Medicare beneficiaries, significantly lowering their out-of-pocket costs for these medications—potentially by up to 95 percent.
Additionally, an estimated 4 million adults on Medicaid would gain access to these vital treatments. This proposal is seen as a way to allow patients and their healthcare providers to make more informed decisions about their health, without the heavy financial burden often associated with these prescriptions.
Many Americans find these medications financially out of reach, with costs soaring to nearly $1,000 per month without insurance coverage. Currently, GLP-1 receptor agonists like Ozempic and Wegovy are typically prescribed for managing type 2 diabetes and aiding weight loss.
According to estimates, around 42 million people in the U.S. currently struggle with obesity, which can lead to various health complications, including heart disease, diabetes, and certain types of cancer. Medical professionals have noted that these new treatments can slow down digestion, helping people manage their weight more effectively.
The administration believes that these advancements in the treatment of obesity mark a significant step forward, potentially decreasing mortality rates and improving overall health outcomes for those suffering from obesity-related conditions.
